MX341536B - Epitopo y anticuerpos beta amiloide de oligomero especifico. - Google Patents

Epitopo y anticuerpos beta amiloide de oligomero especifico.

Info

Publication number
MX341536B
MX341536B MX2012010175A MX2012010175A MX341536B MX 341536 B MX341536 B MX 341536B MX 2012010175 A MX2012010175 A MX 2012010175A MX 2012010175 A MX2012010175 A MX 2012010175A MX 341536 B MX341536 B MX 341536B
Authority
MX
Mexico
Prior art keywords
epitope
amino acid
antibody
snk
oligomer
Prior art date
Application number
MX2012010175A
Other languages
English (en)
Spanish (es)
Other versions
MX2012010175A (es
Inventor
R Cashman Neil
Original Assignee
The Univ Of British Columbia *
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44541581&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX341536(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by The Univ Of British Columbia * filed Critical The Univ Of British Columbia *
Publication of MX2012010175A publication Critical patent/MX2012010175A/es
Publication of MX341536B publication Critical patent/MX341536B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
MX2012010175A 2010-03-03 2011-03-03 Epitopo y anticuerpos beta amiloide de oligomero especifico. MX341536B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31016710P 2010-03-03 2010-03-03
PCT/CA2011/000238 WO2011106885A1 (en) 2010-03-03 2011-03-03 Oligomer-specific amyloid beta epitope and antibodies

Publications (2)

Publication Number Publication Date
MX2012010175A MX2012010175A (es) 2012-11-23
MX341536B true MX341536B (es) 2016-08-24

Family

ID=44541581

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012010175A MX341536B (es) 2010-03-03 2011-03-03 Epitopo y anticuerpos beta amiloide de oligomero especifico.

Country Status (17)

Country Link
US (3) US9216217B2 (enExample)
EP (2) EP3056510B1 (enExample)
JP (2) JP6190113B2 (enExample)
KR (1) KR101831459B1 (enExample)
CN (1) CN102858796B (enExample)
AU (1) AU2011223456A1 (enExample)
BR (1) BR112012022229A2 (enExample)
CA (1) CA2791538C (enExample)
CL (1) CL2012002438A1 (enExample)
CO (1) CO6640211A2 (enExample)
IL (1) IL221695B (enExample)
MX (1) MX341536B (enExample)
NZ (1) NZ602548A (enExample)
RU (1) RU2644335C2 (enExample)
SG (1) SG183854A1 (enExample)
WO (1) WO2011106885A1 (enExample)
ZA (1) ZA201206916B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2644335C2 (ru) 2010-03-03 2018-02-08 Зе Юниверсити Оф Бритиш Коламбия Эпитоп, специфичный к олигомеру амилоида бета, и антитела
TWI571207B (zh) 2011-06-26 2017-02-21 安麗托克斯公司 用於條件化動物飼料之寒冷天氣調配物
CA2855669A1 (en) * 2011-11-10 2013-05-16 Cangene U.S., Incorporated Compositions and methods for treating alzheimer's disease
CN104380111B (zh) * 2012-04-05 2017-08-29 于利希研究中心有限公司 包含多价结合淀粉样β蛋白的D‑肽的聚合物及其应用
WO2015113169A1 (en) * 2014-02-03 2015-08-06 Cnj Holdings, Inc. Humanized beta-amyloid binding molecules and uses thereof
WO2016008047A1 (en) * 2014-07-14 2016-01-21 Cangene Corporation Cyclic peptide vaccination for treatment of amyloid beta-related disorders
CA3004593A1 (en) 2015-11-09 2017-05-18 The University Of British Columbia Systems and methods for predicting misfolded protein epitopes by collective coordinate biasing
CN108350051A (zh) * 2015-11-09 2018-07-31 英属哥伦比亚大学 淀粉样蛋白β中的N-末端表位及其构象选择性抗体
US20180326027A1 (en) * 2015-11-09 2018-11-15 The University Of British Columbia Epitopes in amyloid beta and conformationally-selective antibodies thereto
CA3004498A1 (en) * 2015-11-09 2017-05-18 Neil R. Cashman Amyloid beta epitopes and antibodies thereto
AU2016354688B2 (en) 2015-11-09 2021-12-16 The University Of British Columbia Epitopes in Amyloid beta mid-region and conformationally-selective antibodies thereto
EP3484919A4 (en) 2016-07-18 2020-03-04 The University of British Columbia ANTI-BETA-AMYLOID ANTIBODIES
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
US12286469B2 (en) 2017-07-18 2025-04-29 The University Of British Columbia Humanized antibodies binding to amyloid-beta (A-beta)
AU2018308088B2 (en) 2017-07-25 2025-05-29 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
WO2020033756A1 (en) * 2018-08-09 2020-02-13 F. Hoffmann-La Roche Ag Determination of parkinson's disease
AU2019356804B2 (en) * 2018-10-07 2025-05-29 Promis Neurosciences, Inc. Conformation-specific epitopes in alpha-synuclein, antibodies thereto and methods related thereof
US12352719B2 (en) 2019-09-20 2025-07-08 KYCERA AVX Components Corporation Somatic cell-based electrical biosensor
US12281166B2 (en) 2020-05-26 2025-04-22 Truebinding, Inc. Methods of treating inflammatory diseases by blocking Galectin-3

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB9021679D0 (en) 1990-10-05 1990-11-21 Gorman Scott David Antibody preparation
US6127977A (en) 1996-11-08 2000-10-03 Cohen; Nathan Microstrip patch antenna with fractal structure
CA2250075C (en) 1996-03-29 2008-06-10 The Trustees Of Boston University Methods for diagnosing and treating alzheimer's disease
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6750324B1 (en) * 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US7252952B2 (en) 2000-03-06 2007-08-07 Rigel Pharmaceuticals, Inc. In vivo production of cyclic peptides for inhibiting protein—protein interaction
US6686443B1 (en) 2000-05-26 2004-02-03 The Regents Of The University Of California Chemical reagents for formation of disulfide bonds in peptides
WO2004092202A1 (en) 2003-04-07 2004-10-28 Novetide, Ltd. Process for production of cyclic peptides
EP1484336A1 (en) 2003-06-02 2004-12-08 Pevion Biotech Ltd. Methods for synthesizing conformationally constrained peptides, peptidometics and the use thereof as synthetic vaccines
US20080044356A1 (en) * 2004-10-22 2008-02-21 Regents Of The University Of Minnesota Assemblies of Oligomeric Amyloid Beta Protein and Uses Thereof
IL169622A0 (en) 2005-07-11 2007-07-04 Yeda Res & Dev Methods of screening modulators of interleukin-32 (il-32)modulators of il-32 identified by said methods and their use
US20090297534A1 (en) * 2005-07-13 2009-12-03 Sudhir Paul Catalytic Immunoglobulins BBK32 and Uses Therefor
WO2007103739A2 (en) 2006-03-01 2007-09-13 The University Of Utah Research Foundation Methods and compositions related to cyclic peptide synthesis
CN101622276B (zh) 2006-07-18 2015-04-22 赛诺菲-安万特 用于治疗癌症的抗epha2的拮抗抗体
ES2397641T3 (es) * 2008-07-01 2013-03-08 De Staat Der Nederlanden, Vert. Door De Minister Van Vws Vacuna contra el intermediario de plegado amiloide
US20110092445A1 (en) * 2008-07-25 2011-04-21 Abbott Laboratories Amyloid ß peptide analogues, oligomers thereof, processes for preparing and composi-tions comprising said analogues or oligomers, and their uses
US20100173828A1 (en) 2008-07-25 2010-07-08 Abbott Gmbh & Co. Kg Aß(X - 38 .. 43) oligomers, and processes, compositions, and uses thereof
US8410243B2 (en) 2008-12-17 2013-04-02 The Governors Of The University Of Alberta Aromatic ether-containing fluorene monomers, processes for their preparation and polymerization thereof
AU2009330124A1 (en) 2008-12-22 2011-07-14 Sloan-Kettering Institute For Cancer Research Coumarin-based compounds for the treatment of Alzheimer's disease and cancer
EP2534490B1 (en) 2010-02-09 2015-12-16 Bristol-Myers Squibb Company Immunoassay standards and measurement of clinical biomarkers using intra-assay calibration standards
RU2644335C2 (ru) 2010-03-03 2018-02-08 Зе Юниверсити Оф Бритиш Коламбия Эпитоп, специфичный к олигомеру амилоида бета, и антитела
US9320793B2 (en) 2010-07-14 2016-04-26 Acumen Pharmaceuticals, Inc. Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42
CA2855669A1 (en) 2011-11-10 2013-05-16 Cangene U.S., Incorporated Compositions and methods for treating alzheimer's disease

Also Published As

Publication number Publication date
CA2791538C (en) 2019-04-16
RU2644335C2 (ru) 2018-02-08
MX2012010175A (es) 2012-11-23
JP6190113B2 (ja) 2017-08-30
WO2011106885A1 (en) 2011-09-09
US20130084283A1 (en) 2013-04-04
RU2012139043A (ru) 2014-04-10
CA2791538A1 (en) 2011-09-09
IL221695B (en) 2019-01-31
EP2542571A4 (en) 2013-07-31
CN102858796A (zh) 2013-01-02
EP3056510A1 (en) 2016-08-17
US9849165B2 (en) 2017-12-26
SG183854A1 (en) 2012-10-30
BR112012022229A2 (pt) 2016-07-05
CN102858796B (zh) 2016-05-11
CO6640211A2 (es) 2013-03-22
ZA201206916B (en) 2014-03-26
EP2542571B1 (en) 2016-05-25
AU2011223456A1 (en) 2012-10-18
JP6494565B2 (ja) 2019-04-03
EP2542571A1 (en) 2013-01-09
NZ602548A (en) 2014-12-24
US20160228522A1 (en) 2016-08-11
KR101831459B1 (ko) 2018-04-04
JP2013524774A (ja) 2013-06-20
JP2016193914A (ja) 2016-11-17
US9216217B2 (en) 2015-12-22
EP3056510B1 (en) 2018-10-03
KR20130045850A (ko) 2013-05-06
US20140314773A1 (en) 2014-10-23
CL2012002438A1 (es) 2013-09-13

Similar Documents

Publication Publication Date Title
MX341536B (es) Epitopo y anticuerpos beta amiloide de oligomero especifico.
EA201270813A1 (ru) АНТИТЕЛА К N3pGlu БЕТА-АМИЛОИДНОМУ ПЕПТИДУ И ИХ ПРИМЕНЕНИЕ
EA201171388A1 (ru) Гуманизированные антитела, специфичные к протофибриллярной форме бета-амилоидного пептида
MX2009013503A (es) Anticuerpo monoclonal anti-amiloide-beta.
EA201491851A1 (ru) Композиции и способы для лечения болезни альцгеймера
AU2018256498A1 (en) Antibodies to amyloid beta
TW200732348A (en) Monoclonal antibody
WO2014031694A3 (en) Anti-tau antibodies and methods of making and using in treatment of tauopathies
MX341369B (es) Anticuerpo anti-beta-amiloide humanizado seguro y funcional.
EA201000809A1 (ru) АНТИТЕЛА, СПЕЦИФИЧЕСКИЕ В ОТНОШЕНИИ ПРОТОФИБРИЛЛЯРНОЙ ФОРМЫ БЕЛКА β-АМИЛОИДА
MY164376A (en) Phosphospecific antibodies recognizing tau
TR201800669T4 (tr) Alzheimer hastaliğinda tau-aracili patoloji̇ni̇n tanilanmasi ve protei̇n bazli tedavi̇si̇
MX2009003468A (es) Anticuerpo humanizado contra beta amiloide.
MX2011012039A (es) Anticuerpos bloqueadores anti-dkk-1 y sus usos.
EP2403871A4 (en) FOR ABUSED PRION PROTEIN SPECIFIC ANTIBODIES AND EPITOPES
EA201300130A1 (ru) Способ лечения болезни альцгеймера
PH12012501743A1 (en) Antigen binding proteins specific for serum amyloid p component
WO2012021475A3 (en) ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
EA201391097A1 (ru) СОЕДИНЕНИЯ ДЛЯ СНИЖЕНИЯ ВЫРАБОТКИ β-АМИЛОИДА
MX2011012677A (es) Conjugados de albumina-peptido amiloide y usos de los mismos.
MX343873B (es) Ensayo de diagnostico de anticuerpo.
MX2012004448A (es) Clones infecciosos de torque teno virus.
WO2013054110A3 (en) Compositions for binding to amyloid proteins
TH95385B (th) แอนติบอดีที่ได้รับการฮิวมาไนซ์
RU2019123453A (ru) Пептидная вакцина для предупреждения и иммунотерапии деменции альцгеймеровского типа

Legal Events

Date Code Title Description
FG Grant or registration